Arsanis (NASDAQ:ASNS) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Insider & Institutional Ownership

68.7% of Arsanis shares are owned by institutional investors. Comparatively, 48.5% of Applied Genetic Technologies shares are owned by institutional investors. 50.9% of Arsanis shares are owned by insiders. Comparatively, 5.6% of Applied Genetic Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Arsanis and Applied Genetic Technologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arsanis N/A N/A -$33.87 million ($16.23) -0.10
Applied Genetic Technologies $24.19 million 4.97 -$21.30 million ($1.18) -5.62

Applied Genetic Technologies has higher revenue and earnings than Arsanis. Applied Genetic Technologies is trading at a lower price-to-earnings ratio than Arsanis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arsanis and Applied Genetic Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arsanis N/A N/A N/A
Applied Genetic Technologies -88.06% -19.77% -16.57%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Arsanis and Applied Genetic Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arsanis 0 3 1 0 2.25
Applied Genetic Technologies 0 2 3 0 2.60

Arsanis presently has a consensus price target of $18.50, suggesting a potential upside of 1,034.97%. Applied Genetic Technologies has a consensus price target of $7.40, suggesting a potential upside of 11.61%. Given Arsanis’ higher probable upside, equities analysts clearly believe Arsanis is more favorable than Applied Genetic Technologies.

Summary

Arsanis beats Applied Genetic Technologies on 7 of the 12 factors compared between the two stocks.

Arsanis Company Profile

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.